LEADER 03847nam  22005655  450 
001 9910254531803321
005 20251113203241.0
010   $a3-319-30472-0
024 7 $a10.1007/978-3-319-30472-4
035   $a(CKB)3710000000829643
035   $a(DE-He213)978-3-319-30472-4
035   $a(MiAaPQ)EBC4644449
035   $a(PPN)194806111
035   $a(EXLCZ)993710000000829643
100   $a20160812d2016      u|         0
101 0 $aeng
135   $aurnn#008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aSafety of Biologics Therapy $eMonoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins /$fby Brian A. Baldo
205   $a1st ed. 2016.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016.
215   $a1 online resource (XXI, 610 p. 106 illus., 89 illus. in color.)
311 08$a3-319-30470-4 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $a1: Approved Biologics Used For Therapy and their Adverse Effects -- 2: Monoclonal Antibodies: Introduction -- 3: Monoclonal Antibodies Approved for Cancer Therapy -- 4: Other Approved Therapeutic Monoclonal Antibodies -- 5: Cytokines -- 6: Fusion Proteins -- 7: Peptide Hormones -- 8: Glycoprotein Hormones -- 9: Enzymes Approved for Therapy -- 10: Blood Coagulation -- 11: Vaccines -- 12: Botulinum Neurotoxins -- 13: Biosimilars.
330   $aThis long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters.  It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.
606   $aCardiology
606   $aEndocrinology
606   $aGastroenterology
606   $aOncology
606   $aCardiology
606   $aEndocrinology
606   $aGastroenterology
606   $aOncology
615  0$aCardiology.
615  0$aEndocrinology.
615  0$aGastroenterology.
615  0$aOncology.
615 14$aCardiology.
615 24$aEndocrinology.
615 24$aGastroenterology.
615 24$aOncology.
676   $a616.12
700   $aBaldo$b Brian A$4aut$4http://id.loc.gov/vocabulary/relators/aut$0976587
906   $aBOOK
912   $a9910254531803321
996   $aSafety of Biologics Therapy$92544794
997   $aUNINA